Title : Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.

Pub. Date : 2018 Mar

PMID : 29368050






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. RG7388 MDM2 proto-oncogene Homo sapiens
2 PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator. RG7388 MDM2 proto-oncogene Homo sapiens